ß2-AGONISTS IN CHILDHOOD ASTHMA.
J Biol Regul Homeost Agents
; 29(2 Suppl 1): 137-41, 2015.
Article
in En
| MEDLINE
| ID: mdl-26634602
ß2-agonists reduce airflow limitation by improving airway diameter as a consequence of a direct action on airway smooth muscle. ß;2-agonists can be broadly classified according to their duration of action: short-acting ß2-agonists (SABAs), including albuterol, terbutaline and fenoterol, have pharmacodynamics halflives between 2 and 6 h and long-acting ß2-agonists (LABAs), including salmeterol and formoterol, require twice daily treatment. SABAs are often used as needed for asthma exacerbations and before exercise in the presence of exercise-induced bronchospasm. LABAs provide longer symptom control, which is a particularly useful feature for preventing night-time symptoms. There are two main LABAs, salmeterol and formoterol. This review focused on the recent data published on this topic.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Biol Regul Homeost Agents
Journal subject:
BIOLOGIA
/
BIOQUIMICA
Year:
2015
Document type:
Article
Affiliation country:
Italy
Country of publication:
Italy